The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion ...

AbbVie, Shire, Pfizer, Biogen, and Novartis. He received his medical degree from the Second University V Division of General Surgery in Italy and completed post-doctoral research at Beth Israel ...

Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

The U.S. macroeconomic environment remains favorable for investors. Current interest rates are in the range of 4.75-5.00% ...

The US has drawn up a draft plan to end the war between Israel and Hizbollah ... Other companies: Hess, AbbVie, Kraft Heinz, ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. There are three significant reasons for optimism from here. However, the dividend yield ...

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...